Newer peritoneal dialysis solutions

Advances in Renal Replacement Therapy

Volumn 7, Issue 4, 2000, Pages 302-309

  Gokal, R ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Amino acids; Bicarbonate; Glucose; Icodextrin; PD solutions

Indexed keywords

AMINO ACID; BICARBONATE; GLUCOSE; ICODEXTRIN;

DEGRADATION; DIALYSATE; ELECTROLYTE DISTURBANCE; FLUID RETENTION; PERITONEAL DIALYSIS; PRIORITY JOURNAL; REVIEW; WASTE;

EID: 0033779157     PISSN: 10734449     EISSN: None     Source Type: Journal    
DOI: 10.1053/jarr.2000.16267     Document Type: Article

References (78)

1. Reduplicated basal lamina of small venules and mesothelium of human peritoneal membrane
2. New concepts in molecular biology and ultrastructural pathology of the peritoneum: Their significance for peritoneal dialysis
3. Peritoneal vascular changes in CAPD: An in vivo model for the study of diabetic microangiopathy
4. Long-term effects of peritoneal dialysis on peritoneal morphology
5. Morphological changes in the peritoneal vasculature of patients on CAPD with ultrafiltration failure
6. Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD
7. Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis
8. Sclerosing peritonitis: The experience in Australia
9. National comparisons: Optimal peritoneal dialysis outcomes among Japanese patients
10. Analysis of ultrafiltration failure in peritoneal dialysis patients by means of standard peritoneal permeability analysis
11. What really happens to people on long-term peritoneal dialysis?
12. Longitudinal changes in peritoneal kinetics: The effect of peritoneal dialysis and peritonitis
13. Functional longevity of the human peritoneum: How long is continuous peritoneal dialysis possible? Results of a prospective medium-term study
14. Does impaired transcellular water transport contribute to net ultrafiltration failure during CAPD?
15. Role of transcellular water channels in peritoneal dialysis
16. Glucose and insulin metabolism in uremia
17. Sequential changes in serum lipids and their sub-fractions in patients receiving CAPD
18. Conventional and newer peritoneal dialysis solutions
19. Biocompatibility studies on peritoneal cells
20. Bicarbonate/lactate and bicarbonate buffered peritoneal dialysis fluids improveex vivo peritoneal macrophage TNF alpha secretion
21. Effect of lactate buffered peritoneal dialysis fluid on human peritoneal mesothelial cells, interleukin-6 and prostaglandin synthesis
22. Improved cell function in pyruvate-buffered peritoneal dialysis fluids is related to specific antagonism of the polyol pathway
23. Vascular proliferation and enhanced expression of endothelial nitric oxide synthase in human peritoneum exposed to long-term peritoneal dialysis
24. Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis
25. Accumulation of advanced glycation end products in the vasculature of CAPD patients with low ultra-filtration
26. Immunohistochemical study of human advanced glycosylation end products (AGE) in chronic renal failure
27. The pathogenesis and consequences of AGE formation in uraemia and its treatment
28. Are aldehydes in heat Sterilised peritoneal dialysis fluids toxic in vitro?
29. Clinical and physiological effects of a new, less toxic and less acidic solution for peritoneal dialysis
30. Ultrafiltration with an isosmotic solution during long peritoneal dialysis exchanges
31. Lower carbonyl stress in polyglucose or amino acid PD solutions than in conventional glucose based PD fluids
32. Glycation and advanced end-product formation with icodextrin and dextrose
33. Icodextrin avoids the enhancement of inducible nitric oxide (iNOS) activity in peritoneal mesothelial cells given by glucose solutions
34. A randomised multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose in CAPD
35. Icodextrin 7.5% dialysate solution (glucose polymer) in patients with ultrafiltration failure: Extension of CAPD technique survival
36. Improvement of transcellular water transport by treatment with glucose free dialysate in patients with UF failure
37. Icodextrin instead of glucose during the long day time dwell in CCPD patients increases ultrafiltration and 24-h dialysate creatinine clearance
38. Comparison of icodextrin and glucose solutions for the daytime dwell in automated peritoneal dialysis
39. Peritoneal transport characteristics with glucose polymer based dialysate
40. Peritoneal fluid and solute transport with different polyglucose formulations
41. Peritonitis occurrence in a multicentre study of icodextrin and glucose in CAPD
42. Effect of peritonitis on peritoneal transport characteristics: Glucose versus polyglucose solution
43. Kinetics of icodextrin
44. Icodextrin hypersensitivity in a CAPD patient
45. Short-term studies in the use of amino acids as an osmotic agent in CAPD
46. Six-month prospective cross-over study to determine the effects of 1.1% amino acid dialysate on lipid metabolism in patients on CAPD
47. Treatment of malnourished CAPD patients with an amino acid based dialysate
48. Clinical evaluation of an optimised 1.1% amino acid solution for peritoneal dialysis
49. Treatment of malnutrition with 1.1% amino acid peritoneal dialysis solution: Results of a multicentre outpatient study
50. Six-month overnight intraperitoneal amino acid infusion on CAPD patients: No effect on nutritional status
51. Fasting plasma amino acids are not normalised by 12-month amino-acid-based dialysate in CAPD patients
52. Extended use of glycerol containing dialysate in diabetic CAPD patients
53. Potential hazards of glycerol dialysate in diabetic CAPD patients
54. Glucose and glycerol compared as osmotic agents for peritoneal dialysis
55. Are aldehydes in heat-sterilised peritoneal dialysis fluids toxic in vitro?
56. Less infusion pain and elevated levels of cancer antigen 125 by the use of a new and more biocompatible PD fluid
57. Reduced glucose degradation products in bicarbonate/lactate-buffered peritoneal dialysis solutions produced in two-chambered bags
58. Loss of ultrafiltration in CAPD: Role for acetate
59. The effect of dialysate on peritoneal phagocyte oxidative metabolism
60. Peritoneal dialysis fluid inhibition of neutrophil function is mediated by high osmolality and/or the lowering of intracellular pH
61. Biocompatibility and new fluids
62. Bicarbonate/lactate and bicarbonate buffered peritoneal dialysis fluids improve ex vivo peritoneal macrophage TNF alpha secretion
63. Effect of lactate buffered peritoneal dialysis fluid on human peritoneal mesothelial cells, interleukin-6 and prostaglandin synthesis
64. Clinical experience with a 39 mmol/1 bicarbonate-buffered peritoneal dialysis solution
65. A randomised controlled trial of a bicarbonate- and bicarbonate/lactate-containing peritoneal dialysis solution
66. Bicarbonate-versus lactate-based CAPD fluids: A biocompatibility study in rabbits
67. In vitro effects of bicarbonate and bicarbonate-lactate buffered peritoneal dialysis solutions on mesothelial cells and neutrophil function
68. A controlled trial of two bicarbonate-containing fluids for CAPD-final report
69. Treatment of infusion pain by bicarbonate and bicarbonate/lactate containing PD solutions
70. Anti-hypertensive effect of low Na concentration (120 mEq/1) solution for CAPD patients
71. Ultrafiltration and solute kinetics using low sodium peritoneal dialysate
72. Towards tailored dialysis fluids in CAPD: The role of reduced calcium and magnesium in dialysis fluids
73. Dialysate calcium reduction in CAPD patients treated with calcium carbonate and alfacalcidol
74. Reduced calcium dialysis fluids: What's the point?
75. Calcium content in automated peritoneal dialysis solutions
76. Strategies to reduce glucose exposure in peritoneal dialysis patients
77. Peritoneal dialysis solutions for the 21st century
78. Innovative peritoneal dialysis: Flow-thru and dialysate regeneration